Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

Tarsus Pharmaceuticals agreed to acquire Alkeus Pharmaceuticals in a cash-and-stock deal worth up to $800 million, adding an experimental oral therapy for a rare inherited retinal disorder that currently has no approved U.S. treatment. The deal expands Tarsus’s pipeline with a late-stage commercial opportunity if the therapy succeeds. Overall, the announcement is a positive catalyst for company fundamentals, though the impact depends on future clinical/regulatory progress.

Analysis

Tarsus Pharmaceuticals agreed to acquire Alkeus Pharmaceuticals in a cash-and-stock deal worth up to $800 million, adding an experimental oral therapy for a rare inherited retinal disorder that currently has no approved U.S. treatment. The deal expands Tarsus’s pipeline with a late-stage commercial opportunity if the therapy succeeds. Overall, the announcement is a positive catalyst for company fundamentals, though the impact depends on future clinical/regulatory progress.